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 Breastfeeding usually meets DHA needs of term (100 mg/d) but not the much higher 27 requirements very low birthweight infants (VLBWI) 28  To match intrauterine DHA accretion, VLBWI require a human milk DHA content of 29 about 1% that can be achieved by maternal supplementation with 3 g/d tuna oil 30  A high milk DHA supply to VLBWI may enhance early visual and cognitive 31 development and reduce adverse events such as severe developmental delay, 32 bronchopulmonary dysplasia, necrotizing enterocolitis and allergies 33  The supply, metabolism and biological effects of the omega-3 (n3) and the omega-6 34 (n-6) essential polyunsaturated fatty acids (PUFA) during pregnancy, infancy and 35 childhood has received considerable attention and has been addressed in numerous 36 research studies, as recently reviewed (1-4). The essential fatty acids omega-6 (n-6) 37 linoleic acid (18:2n-6, LA) and omega-3 (n-3) alpha-linolenic acid (18:3n-3, ALA) 38 found in plants and vegetable oils are the precursors of the biologically active long-39 chain polyunsaturated fatty acids (LC-PUFA). The quantitatively pre-dominant LC-40 PUFA are n-6 arachidonic acid (ARA, 20:4n-6), n-3 eicosapentaenoic acid (20:5n-3, 41 EPA) and n-3 docosahexaenic acid (DHA, . Both during pregnancy and 42 infancy, n-6 and n-3 LC-PUFA are accreted in relatively large amounts in fetal and 43 infant tissues. Particularly high concentrations are found in the brain grey matter and 44 in the rod outer segments of the retina and have been related to functional 45 development such as cognition and visual acuity (4). Some LC-PUFA, including n-6 46 dihomo-gamma-linolenic acid (20:3n-6), ARA, EPA and DHA also serve as 47 precursors of eicosanoids and docosanoids, such as prostaglandins. prostacyclins, 48 leukotrienes and resolvins. In low concentrations, eicosanoids and docosanoids are 49 powerful regulators of numerous physiological processes such as cardiovascular 50 function and the early postnatal closure of the ductus arteriosus Botalli, thrombocyte 51 aggregation and bleeding time, inflammation and immunity, and others. In fact, the 52 early availability of LC-PUFA has been associated with the immune functions and the 53 likelihood of the development of allergies and infections (1).
LC-PUFA can either be provided preformed via the placenta or the dietary sources such as 55 human milk, or they can be endogenously synthesized from the precursors LA and ALA by 56 consecutive desaturation and chain elongation. However, in humans the conversion rates 57 are rather low. It was estimated that only 0.1% to 10% of the precursor fatty acids are 58 converted to LC-PUFA, with a particularly low rate of synthesis for DHA (5-7). The rates of 59 conversion are also very variable depending on genotypes of the fatty acid desaturase 60 (FADS) gene cluster. Individuals with certain genetic haplotypes have extremely low rates of 61 ARA and DHA synthesis and thus depend even more on the supply of preformed LC-PUFA 62 to maintain plasma and tissue levels (1, (8) (9) (10) (11) (12) . In infants, and particularly in preterm infants, 63 the rates of parent PUFA conversion to LC-PUFA are considered insufficient to achieve 64 biochemical and functional normality (13, 14) . 65
In utero, ARA and DHA are supplied preformed to the fetus by way of an active and 66 preferential materno-fetal transport across the placenta that we have measured in vivo using 67 fatty acids labelled with stable isotopes (15, 16 (fatty acid transport proteins) -1 to -6 (17, 19). In the cytosol, fatty acids are bound to fatty 78 acid binding proteins (FABPs) leading to interaction with subcellular organelles, including the 79 endoplasmic reticulum, mitochondria, lipid droplets and peroxisomes. FABPs are also likely 80 to function in the nucleus through the delivery of specific ligands to nuclear transcription 81 factors, such as the peroxisome proliferator-activated receptors (PPAR). This complexsystem achieves an active placental materno-fetal transfer of ARA and particularly of DHA. 83
Given that intrauterine growth and body composition is generally considered the reference 84 that postnatal care of preterm infants should match as much as feasible, it appears prudent 85 to aim at approaching the degree of intrauterine provision of preformed LC-PUFA with 86 postnatal nutritional regimens. 87
After birth, breastfed infants always receive preformed ARA and DHA with human milk lipids. 88
The milk fatty acid composition is modified by maternal diet, lipolysis of body fat stores that 89 markedly contribute to milk fat synthesis, maternal genotype, and stage of lactation (11, 20, 90 21) . Around the world, human milk provides a relatively stable ARA supply around 0.5 % of 91 milk fatty acids, whereas DHA is found at a mean level of 0.3 % but shows much more 92 variation primarily due to differences in maternal intake of dietary DHA sources such as fish 93 and seafood (21, 22) . Full breastfeeding usually meets the recommended intakes for term 94 born infants of 140 mg ARA/day and 100 mg DHA/day (1, 23) but not the higher 95 recommended intakes for preterm infants. Although the milk of mothers of preterm women 96 contains slightly higher amounts of LC-PUFA (24), the recommended DHA supply of very low 97 birthweight infants can only be met through human milk if women obtain a markedly 98 increased DHA intake. The human milk DHA content is linearly related to the maternal DHA 99 intake, as we documented in a supplementation study of well-nourished mothers who fully 100 breastfed their infants born at term (25) 101 102
LC-PUFA supply to preterm infants 103
Increasing DHA provision to preterm infants through DHA supplements to the lactating 104 mother needs to be justified by indications for a benefit for clinical outcome. The recent 105 systematic review of the Early Nutrition Academy on the roles of pre-and postnatal long-106 chain polyunsaturated fatty acids (LC-PUFA) included studies in preterm infants published 107 until 2013 (1). The LC-PUFA provision to preterm infants was also evaluated in a meta-108 analysis of available studies (26) and in recent reviews (2, 27). Most of the available studies 109 in preterm infants evaluated DHA supplies with human milk or formula of about 0.2-0.3 % of 110 fat, as often provided to healthy infants born at term. However, this level of supply is not 111 sufficient to achieve the estimated daily intrauterine deposition of DHA of 43 mg/kg body 112 weight, which occurs along with an even high ARA deposition of about 212 mg/kg (28). It has 113 been estimated that the intrauterine DHA accretion rate may be matched postnatally in 114 preterm infants by DHA provision amount to 1% of human milk or formula fat (29). This 115 approach has been evaluated in randomized trials that studied the addition of LC-PUFA-rich 116 oils to human milk (30) or the supplementation of mothers providing human milk with LC-117 PUFA-rich marine oil (31-34). 118
119

Visual and cognitive development 120
The Cochrane meta-analysis by Schulzke et al found no benefit of an added LC-PUFA 121 supply to preterm infants on cognitive outcomes at the age of 12 to 18 months in 4 out of 7 122 studies included in this meta-analysis (26). Of interest, the three studies that found such 123 benefits used the newer version II of the "Bayley Scales of Infant Development", which raises 124 the question whether the older version of the Bayley test or other tests might not be as 125 sensitive to detect effects. Visual acuity was not found to be influenced by LC-PUFA supply 126
(26). 127
Of particular interest are the findings of two large studies providing much higher DHA 128 amounts with milk and hence approaching more closely the levels of intrauterine supply. 129
Henriksen et al (2008) randomized 141 very low birthweight infants to an intervention adding 130
an LC-PUFA-rich algal oil, mixed with soy oil and medium-chain triglyceride oil. The 131 intervention provided an added 32 mg of DHA and 31 mg of ARA per 100 mL of human milk 132 and started at one week after birth, with continuation until discharge from the hospital which 133 occurred on average after nine weeks. Cognitive development was evaluated at 6 months of 134 age by the "Ages and Stages Questionnaire" and event-related potentials, a measure of 135 brain correlates related to recognition memory. At the 6-month follow-up, the authors found a 136 better performance of the intervention group on the problem-solving subscore, compared 137 with the control group (53.4 vs 49.5 points). There was also a nonsignificant trend to a higher 138 total score (221 vs 215 points). The event-related potential data revealed that infants in the 139 intervention group had significantly lower responses after the standard image, compared with 140 the control group (8.6 vs 13.2). Further follow-up to the age of 8 years did not indicate any 141 significant differences at school age with regards to brain structure, cognition and behaviour 142 (35, 36) . 143
Makrides and coworkers performed a very large randomized multicentre trial enrolling as 144 many as 657 preterm infants who were provided with a conventional (0.35 %) or high (1 %) 145 DHA supply from day 2-4 of life until term. The higher DHA provision was achieved by 146 supplementation of women providing human milk with a daily dose of 3 g of tuna oil, or by a 147 preterm formula with increased DHA content, along with about 0.5 % ARA (31-34). No 148 adverse effects of supplementation were observed in the infants. The higher DHA supply 149 improved visual acuity development at the corrected age of 4 months, with an acuity that was 150 1.4 cycles per degree higher than in the control group (Table 1) (37). The Bayley test of 151 infant development (version II) was applied at an age of 18 months, corrected for gestational 152 age. While no significant benefit of the intervention was detected in the total study 153 population, improved cognitive development was found in girls, and in the group of smaller 154 infants with a birthweight less than 1250 g (Table 1 ). Probably of even greater clinical 155 importance, the rate of children with severe developmental retardation (Mental Development 156 Index <70) was reduced by half (Table 1) . Later follow-up to the age of 7 years did not 157 indicate any significant differences at school age with regards to cognition, behaviour and 158 visual function (38) (39) (40) . 159
160
Effects on other outcomes 161
In the previously cited trial with 657 preterm infants provided with conventional (0.35 %) or 162 high (1 %) levels of DHA in the milk supplied, the occurrence of chronic lung disease 163 new trial to revisit this important effect has been initiated (41). A meta-analysis including 18 168 randomized controlled trials found that n-3 LC-PUFA supply was not associated with a 169 decreased risk of BPD in all studied preterm infants, but trials that included only infants born 170 at ≤32 weeks of found a trend toward reduced BPD (pooled RR 0.88, 95% CI 0.74-1.05, 7 171 studies, n = 1156 infants) along with a reduction in the risk of necrotizing enterocolitis (pooled 172 RR 0.50, 95% CI 0.23-1.10, 5 studies, n = 900 infants (42). 173
The preterm trial by Makrides et al. providing either 0.3 % or 1 % of milk fatty acids as DHA 174 also evaluated the incidence of atopic conditions up to the age of 18 months. (32). There was 175 no effect on duration of respiratory support, admission length, or home oxygen requirement. 176
There was a reduction in reported hay fever in all infants in the high-DHA group at either 12 177 or 18 months (RR: 0.41 [95% CI: 0.18-0.91]; P=.03) and at either 12 or 18 months in boys 178 (RR: 0.15 [0.03-0.64]; P=.01), while there was no effect on asthma, eczema, or food allergy. 179
A recent Cochrane review evaluated published data on effects of pre-or postnatal n-3 LC-180 PUFA supplementation to women during pregnancy or the or breastfeeding period on allergy 181 outcomes in their children (43) . Although the data were derived from a limited number of 182 informative randomized trials, an added n-3 LC-PUFA supply reduced the risk of any 183 medically diagnosed, IgE mediated allergy in children aged 12 to 36 months (risk ratio 0.66, 184 95% confidence interval 0.44 to 0.98) but not after the age of 36 months Food allergies were 185 no different after the age of 1 year, but a clear reduction was seen for infants. Also, medically 186 diagnosed IgE-mediated eczema was reduced by maternal n-3 LC-PUFA supply at the age 187 of 1-3 years but not at other ages (43). These data point to possible benefits of a higher n-3 188 LC-PUFA supply in early life on allergic and atopic disorders. 
